Viral Pneumonia in Patients with Hematopoietic Cell Transplantation and Hematologic Malignancies

Clinics in Chest Medicine

Volumn 38, Issue 2, 2017, Pages 295-305

  Green, Margaret L ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

Community respiratory virus infection; Cytomegalovirus; Hematologic malignancy; Hematopoietic cell transplantation; Pneumonia

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BENZIMIDAVIR; BRINCIDOFOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; HYBRID PROTEIN; LETERMOVIR; LUMICITABINE; OSELTAMIVIR; PERAMIVIR; PRESATOVIR; RIBAVIRIN; SIALIDASE; VALACICLOVIR; ZANAMIVIR;

ANTIVIRAL THERAPY; DIAGNOSTIC VALUE; EPIDEMIC; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRIDAE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INFECTION PREVENTION; INFLUENZA; LATENT VIRUS INFECTION; LUNG LAVAGE; MORBIDITY; MORTALITY; PARAINFLUENZA VIRUS INFECTION; PRIMARY INFECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY VIRUS; REVIEW; VIRUS PNEUMONIA; VIRUS REACTIVATION; VIRUS RESISTANCE; COMPLICATION; HEMATOLOGIC DISEASE; TRANSPLANTATION CONDITIONING;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PNEUMONIA, VIRAL; TRANSPLANTATION CONDITIONING;

EID: 85018758470     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2016.12.009     Document Type: Review

References (130)

1. 1 Ison, M.G., Hayden, F.G., Kaiser, L., et al. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 36:9 (2003), 1139–1143.
2. 2 Shannon, V.R., Andersson, B.S., Lei, X., et al. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant 45:4 (2009), 647–655.
3. 3 Oren, I., Hardak, E., Zuckerman, T., et al. Does molecular analysis increase the efficacy of bronchoalveolar lavage in the diagnosis and management of respiratory infections in hemato-oncological patients?. Int J Infect Dis 50 (2016), 48–53.
4. 4 Hardak, E., Avivi, I., Berkun, L., et al. Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome. Infection 44:4 (2016), 491–497.
5. 5 Miller, W.T.J., Mickus, T.J., Barbosa, E.J., et al. CT of viral lower respiratory tract infections in adults: comparison among viral organisms and between viral and bacterial infections. AJR Am J Roentgenol 197:5 (2011), 1088–1095.
6. 6 Kanne, J.P., Godwin, J.D., Franquet, T., Viral pneumonia after hematopoietic stem cell transplantation: high-resolution CT findings. J Thorac Imaging 22:3 (2007), 292–299.
7. 7 Franquet, T., Rodriguez, S., Martino, R., et al. Thin-section CT findings in hematopoietic stem cell transplantation recipients with respiratory virus pneumonia. AJR Am J Roentgenol 187:4 (2006), 1085–1090.
8. 8 Herbst, T., Van Deerlin, V.M., Miller, W.T.J., The CT appearance of lower respiratory infection due to parainfluenza virus in adults. AJR Am J Roentgenol 201:3 (2013), 550–554.
9. 9 Shiley, K.T., Van Deerlin, V.M., Miller, W.T.J., Chest CT features of community-acquired respiratory viral infections in adult inpatients with lower respiratory tract infections. J Thorac Imaging 25:1 (2010), 68–75.
10. 10 Kim, M.-C., Kim, M.Y., Lee, H.J., et al. CT findings in viral lower respiratory tract infections caused by parainfluenza virus, influenza virus and respiratory syncytial virus. Medicine, 95(26), 2016, e4003.
11. 11 Cheng, G.-S., Stednick, Z., Madtes, D.K., et al. Decline in the use of surgical biopsy for diagnosis of pulmonary disease in hematopoietic cell transplantation recipients in an era of improved diagnostics and empirical therapy. Biol Blood Marrow Transplant 22 (2016), 2243–2249.
12. 12 Osiowy, C., Direct detection of respiratory syncytial virus, parainfluenza virus, and adenovirus in clinical respiratory specimens by a multiplex reverse transcription-PCR assay. J Clin Microbiol 36:11 (1998), 3149–3154.
13. 13 Coiras, M.T., Aguilar, J.C., Garcia, M.L., et al. Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested-PCR assays. J Med Virol 72:3 (2004), 484–495.
14. 14 Templeton, K.E., Scheltinga, S.A., Beersma, M.F.C., et al. Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza a and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4. J Clin Microbiol 42:4 (2004), 1564–1569.
15. 15 Fan, J., Henrickson, K.J., Savatski, L.L., Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin Infect Dis 26:6 (1998), 1397–1402.
16. 16 Choudhary, M.L., Anand, S.P., Heydari, M., et al. Development of a multiplex one step RT-PCR that detects eighteen respiratory viruses in clinical specimens and comparison with real time RT-PCR. J Virol Methods 189:1 (2013), 15–19.
17. 17 van Elden, L., van Kraaij, M., Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia. Clin Infect Dis 34:2 (2002), 177–183.
18. 18 Ljungman, P., Griffiths, P., Paya, C., Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:8 (2002), 1094–1097.
19. 19 Fajac, A., Stephan, F., Ibrahim, A., et al. Value of cytomegalovirus detection by PCR in bronchoalveolar lavage routinely performed in asymptomatic bone marrow recipients. Bone Marrow Transplant 20:7 (1997), 581–585.
20. 20 Cathomas, G., Morris, P., Pekle, K., et al. Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells. Blood 81:7 (1993), 1909–1914.
21. 21 Eriksson, B.M., Brytting, M., Zweygberg-Wirgart, B., et al. Diagnosis of cytomegalovirus in bronchoalveolar lavage by polymerase chain reaction, in comparison with virus isolation and detection of viral antigen. Scand J Infect Dis 25:4 (1993), 421–427.
22. 22 Tan, S.K., Burgener, E.B., Waggoner, J.J., et al. Molecular and culture-based bronchoalveolar lavage fluid testing for the diagnosis of cytomegalovirus pneumonitis. Open Forum Infect Dis, 3(1), 2016, ofv212.
23. 23 Krowka, M.J., Rosenow, E.C., Pulmonary complications of bone marrow transplantation. Chest 87:2 (1985), 237–246.
24. 24 Meyers, J.D., Flournoy, N., Thomas, E.D., Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153:3 (1986), 478–488.
25. 25 Schmidt, G.M., Horak, D.A., Niland, J.C., et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; the City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 324:15 (1991), 1005–1011.
26. 26 Winston, D.J., Ho, W.G., Bartoni, K., et al. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis 10:Suppl 3 (1988), S547–S553.
27. 27 Crumpacker, C., Marlowe, S., Zhang, J.L., et al. Treatment of cytomegalovirus pneumonia. Rev Infect Dis 10:Suppl 3 (1988), S538–S546.
28. 28 Erice, A., Jordan, M.C., Chace, B.A., et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 257:22 (1987), 3082–3087.
29. 29 Erard, V., Guthrie, K.A., Seo, S., et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis 61:1 (2015), 31–39.
30. 30 Goodrich, J.M., Mori, M., Gleaves, C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:23 (1991), 1601–1607.
31. 31 Winston, D.J., Ho, W.G., Bartoni, K., et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118:3 (1993), 179–184.
32. 32 Boeckh, M., Gooley, T.A., Myerson, D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood, 88(10), 1996, 4063.
33. 33 Nguyen, Q., Champlin, R., Giralt, S., et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 28:3 (1999), 618–623.
34. 34 Ljungman, P., Perez-Bercoff, L., Jonsson, J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91:1 (2006), 78–83.
35. 35 Marty, F.M., Ljungman, P., Papanicolaou, G.A., et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11:4 (2011), 284–292.
36. 36 Green, M.L., Leisenring, W., Stachel, D., et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 18:11 (2012), 1687–1699.
37. 37 Boeckh, M., Leisenring, W., Riddell, S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:2 (2003), 407–414.
38. 38 Boeckh, M., Nichols, W.G., Chemaly, R.F., et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation. Ann Intern Med, 162(1), 2015, 1.
39. 39 Miller, W., Flynn, P., McCullough, J., et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood, 67(4), 1986, 1162.
40. 40 Dahi, P.B., Perales, M.A., Devlin, S.M., et al. Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. Leuk Lymphoma 56:6 (2015), 1799–1805.
41. 41 Milano, F., Pergam, S.A., Xie, H., et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 118:20 (2011), 5689–5696.
42. 42 Hertenstein, B., Hampl, W., Bunjes, D., et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 15:3 (1995), 387–393.
43. 43 van Burik, J.-A.H., Carter, S.L., Freifeld, A.G., et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 13:12 (2007), 1487–1498.
44. 44 Chemaly, R.F., Torres, H.A., Hachem, R.Y., et al. Cytomegalovirus pneumonia in patients with lymphoma. Cancer 104:6 (2005), 1213–1220.
45. 45 Nguyen, Q., Estey, E., Raad, I., et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis 32:4 (2001), 539–545.
46. 46 Konoplev, S., Champlin, R.E., Giralt, S., Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Transplantation 27:8 (2001), 877–881.
47. 47 Ljungman, P., Biron, P., Bosi, A., et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious disease working party of the European Group for bone marrow transplantation. Bone Marrow Transplant 13:2 (1994), 209–212.
48. 48 Jain, R., Trehan, A., Mishra, B., et al. Cytomegalovirus disease in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 33:4 (2016), 239–247.
49. 49 Boeckh, M., Ljungman, P., How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:23 (2009), 5711–5719.
50. 50 Emanuel, D., Cunningham, I., Jules-Elysee, K., et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 109:10 (1988), 777–782.
51. 51 Reed, E.C., Bowden, R.A., Dandliker, P.S., et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 109:10 (1988), 783–788.
52. 52 Schmidt, G.M., Kovacs, A., Zaia, J.A., et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 46:6 (1988), 905–907.
53. 53 Machado, C.M., Dulley, F.L., Boas, L.S., et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant 26:4 (2000), 413–417.
54. 54 Ljungman, P., Engelhard, D., Link, H., et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 14:4 (1992), 831–835.
55. 55 Lurain, N.S., Chou, S., Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23:4 (2010), 689–712.
56. 56 Avery, R.K., Arav-Boger, R., Marr, K.A., et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection. Transplantation 100:10 (2016), e74–e80.
57. 57 Choi, S.H., Hwang, J.-Y., Park, K.-S., et al. The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations. Transpl Infect Dis 16:6 (2014), 919–929.
58. 58 Eckle, T., Prix, L., Jahn, G., et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96:9 (2000), 3286–3289.
59. 59 Avery, R.K., Marty, F.M., Strasfeld, L., et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 12:6 (2010), 489–496.
60. 60 Schubert, A., Ehlert, K., Schuler-Luettmann, S., et al. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis, 13, 2013, 330.
61. 61 Chou, S., Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis 28:4 (2015), 293–299.
62. 62 Kaul, D.R., Stoelben, S., Cober, E., et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 11:5 (2011), 1079–1084.
63. 63 Locksley, R.M., Flournoy, N., Sullivan, K.M., et al. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 152:6 (1985), 1172–1181.
64. 64 Koc, Y., Miller, K.B., Schenkein, D.P., et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 6:1 (2000), 44–49.
65. 65 Baden, L.R., Bensinger, W., Angarone, M., Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 10:11 (2012), 1412–1445.
66. 66 Tomblyn, M., Chiller, T., Einsele, H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15:10 (2009), 1143–1238.
67. 67 Boeckh, M., Kim, H.W., Flowers, M.E.D., et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study. Blood 107:5 (2006), 1800–1805.
68. 68 Erard, V., Guthrie, K.A., Varley, C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110:8 (2007), 3071–3077.
69. 69 Perren, T.J., Powles, R.L., Easton, D., et al. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med 85:2A (1988), 99–101.
70. 70 Kim, D.H., Kumar, D., Messner, H.A., et al. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for varicella-zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant 22:6 (2008), 770–779.
71. 71 Kim, D.H., Messner, H., Minden, M., et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 10:2 (2008), 90–98.
72. 72 Weinstock, D.M., Eagan, J., Malak, S.A., et al. Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol 21:11 (2000), 730–732.
73. 73 Mattner, F., Sykora, K.-W., Meissner, B., et al. An adenovirus type F41 outbreak in a pediatric bone marrow transplant unit. Pediatr Infect Dis J 27:5 (2008), 419–424.
74. 74 Abdallah, A., Rowland, K.E., Schepetiuk, S.K., et al. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant 32:2 (2003), 195–203.
75. 75 Hodson, A., Kasliwal, M., Streetly, M., et al. A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality. Bone Marrow Transplant 46:12 (2011), 1545–1550.
76. 76 Chu, H.Y., Englund, J.A., Podczervinski, S., et al. Nosocomial transmission of respiratory syncytial virus in an outpatient cancer center. Biol Blood Marrow Transplant 20:6 (2014), 844–851.
77. 77 Campbell, A.P., Guthrie, K.A., Englund, J.A., et al. Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis 61:2 (2015), 192–202.
78. 78 de Lima, C.R.A., Mirandolli, T.B., Carneiro, L.C., et al. Prolonged respiratory viral shedding in transplant patients. Transpl Infect Dis 16:1 (2014), 165–169.
79. 79 Lehners, N., Tabatabai, J., Prifert, C., et al. Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders. PLoS One, 11(2), 2016, e0148258.
80. 80 Nichols, W.G., Guthrie, K.A., Corey, L., et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39:9 (2004), 1300–1306.
81. 81 Chemaly, R.F., Ghosh, S., Bodey, G.P., et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients. Medicine 85:5 (2006), 278–287.
82. 82 Yousuf, H.M., Englund, J., Couch, R., et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis 24:6 (1997), 1095–1099.
83. 83 Ljungman, P., Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 7:Suppl (2001), 5S–7S.
84. 84 Choi, S.-M., Boudreault, A.A., Xie, H., et al. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 117:19 (2011), 5050–5056.
85. 85 Tramontana, A.R., George, B., Hurt, A.C., et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 16:7 (2010), 1068–1075.
86. 86 Couturier, B.A., Bender, J.M., Schwarz, M.A., et al. Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients. Influenza Other Respir Viruses 4:4 (2010), 199–204.
87. 87 Pollara, C.P., Piccinelli, G., Rossi, G., et al. Nosocomial outbreak of the pandemic influenza A (H1N1) 2009 in critical hematologic patients during seasonal influenza 2010-2011: detection of oseltamivir resistant variant viruses. BMC Infect Dis, 13, 2013, 127.
88. 88 Renaud, C., Kuypers, J., Englund, J.A., Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J Clin Virol 52:2 (2011), 70–78.
89. 89 Yu, Y., Garg, S., Yu, P.A., et al. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. Clin Infect Dis 55:1 (2012), 8–15.
90. 90 Hernandez, J.E., Adiga, R., Armstrong, R., et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 52:6 (2011), 695–706.
91. 91 Muthuri, S.G., Venkatesan, S., Myles, P.R., et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2:5 (2014), 395–404.
92. 92 Shahgholi, E., Ehsani, M.A., Salamati, P., et al. Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatr Blood Cancer 54:5 (2010), 716–720.
93. 93 Cheuk, D.K.L., Chiang, A.K.S., Lee, T.L., et al. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev, 3, 2011, CD006505.
94. 94 Baden, L.R., Swaminathan, S., Angarone, M., et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14:7 (2016), 882–913.
95. 95 Rubin, L.G., Levin, M.J., Ljungman, P., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:3 (2014), e44–e100.
96. 96 Engelhard, D., Nagler, A., Hardan, I., et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 11:1 (1993), 1–5.
97. 97 Engelhard, D., Mohty, B., La Camara de, R., et al. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis 15:3 (2013), 219–232.
98. 98 Nichols, W.G., Gooley, T., Boeckh, M., Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 7:Suppl (2001), 11S–15S.
99. 99 Martino, R., Porras, R.P., Rabella, N., et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 11:10 (2005), 781–796.
100. 100 Shah, D.P., Ghantoji, S.S., Shah, J.N., et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 68:8 (2013), 1872–1880.
101. 101 Shah, D.P., Ghantoji, S.S., Ariza-Heredia, E.J., et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood 123 (2014), 1–7.
102. 102 Waghmare, A., Campbell, A.P., Xie, H., et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis 57:12 (2013), 1731–1741.
103. 103 Khanna, N., Widmer, A.F., Decker, M., et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 46:3 (2008), 402–412.
104. 104 Hirsch, H.H., Martino, R., Ward, K.N., et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 56:2 (2012), 258–266.
105. 105 Chemaly, R.F., Aitken, S.L., Wolfe, C.R., et al. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis 18:4 (2016), 634–636.
106. 106 Beaird, O.E., Freifeld, A., Ison, M.G., et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 18:2 (2016), 210–215.
107. 107 DeVincenzo, J.P., McClure, M.W., Symons, J.A., et al. Activity of Oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 373:21 (2015), 2048–2058.
108. 108 DeVincenzo, J.P., Whitley, R.J., Mackman, R.L., et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371:8 (2014), 711–722.
109. 109 Erard, V., Chien, J.W., Kim, H.W., et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 193:12 (2006), 1619–1625.
110. 110 Chemaly, R.F., Hanmod, S.S., Rathod, D.B., et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 119:12 (2012), 2738–2745.
111. 111 Srinivasan, A., Wang, C., Yang, J., et al. Parainfluenza virus infections in children with hematologic malignancies. Pediatr Infect Dis J 30:10 (2011), 855–859.
112. 112 Wendt, C.H., Weisdorf, D.J., Jordan, M.C., et al. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 326:14 (1992), 921–926.
113. 113 Schiffer, J.T., Kirby, K., Sandmaier, B., et al. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 94:8 (2009), 1101–1108.
114. 114 Nichols, W.G., Corey, L., Gooley, T., et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 98:3 (2001), 573–578.
115. 115 Waghmare, A., Wagner, T., Andrews, R., et al. Successful treatment of parainfluenza virus respiratory tract infection with DAS181 in 4 immunocompromised children. J Pediatr Infect Dis Soc 4:2 (2015), 114–118.
116. 116 Chen, Y.-B., Driscoll, J.P., McAfee, S.L., et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis 53:7 (2011), e77–e80.
117. 117 de Mezerville, M.H.N., Tellier, R., Richardson, S., et al. Adenoviral infections in pediatric transplant recipients. Pediatr Infect Dis J 25:9 (2006), 815–818.
118. 118 Roch, N., Salameire, D., Gressin, R., et al. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome. Scand J Infect Dis 40:4 (2009), 343–346.
119. 119 Karlsson, C., Lundin, J., Kimby, E., et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 144:1 (2009), 78–85.
120. 120 Bruno, B., Gooley, T., Hackman, R.C., et al. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 9:5 (2003), 341–352.
121. 121 Baldwin, A., Kingman, H., Darville, M., et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 26:12 (2000), 1333–1338.
122. 122 Matthes-Martin, S., Feuchtinger, T., Shaw, P.J., et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis 14:6 (2012), 555–563.
123. 123 Yusuf, U., Hale, G.A., Carr, J., et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 81:10 (2006), 1398–1404.
124. 124 Legrand, F., Berrebi, D., Houhou, N., et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 27:6 (2001), 621–626.
125. 125 Oliveira, R.R., Machado, A.F., Tateno, A.F., et al. Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years. Bone Marrow Transplant 42:4 (2008), 265–269.
126. 126 Rattray, R.M., Press, R.D., The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. J Clin Virol 68 (2015), 1–5.
127. 127 Renaud, C., Xie, H., Seo, S., et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant 19:8 (2013), 1220–1226.
128. 128 Seo, S., Gooley, T.A., Kuypers, J.M., et al. Human metapneumovirus infections following hematopoietic cell transplantation: factors associated with disease progression. Clin Infect Dis 63:2 (2016), 178–185.
129. 129 Dykewicz, C.A. National Center for Infectious Diseases, Centers for Disease Control and Prevention Infectious Diseases Society of America, American Society for Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant 7:Suppl (2001), 19S–22S.
130. 130 Sullivan, K.M., Dykewicz, C.A., Longworth, D.L., et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematol Am Soc Hematol Educ Program, 2001, 392–421.